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Abstract
Background Galactomannan antigen (GM) testing is widely used in the diagnosis of invasive aspergillosis (IA). Digestive 
enzymes play an important role in enzyme substitution therapy in exocrine pancreatic insufficiency. As digestive enzymes 
of fungal origin like Nortase contain enzymes from Aspergillus, a false-positive result of the test might be possible because 
of cross-reacting antigens of the cell wall of the producing fungi. We, therefore, asked whether the administration of fungal 
enzymes is a relevant cause of false-positive GM antigen test results.
Methods Patients with a positive GM antigen test between January 2016 and April 2020 were included in the evaluation and 
divided into two groups: group 1—Nortase-therapy, group 2—no Nortase-therapy. In addition, dissolved Nortase samples 
were analyzed in vitro for GM and β-1,3-D-glucan. For statistical analysis, the chi-squared and Mann‒Whitney U tests 
were used.
Results Sixty-five patients were included in this evaluation (30 patients receiving Nortase and 35 patients not receiving 
Nortase). The overall false positivity rate of GM testing was 43.1%. Notably, false-positive results were detected significantly 
more often in the Nortase group (73.3%) than in the control group (17.1%, p < 0.001). While the positive predictive value of 
GM testing was 0.83 in the control group, there was a dramatic decline to 0.27 in the Nortase group. In vitro analysis proved 
that the Nortase enzyme preparation was highly positive for the fungal antigens GM and β-1,3-D-glucan.
Conclusions Our data demonstrate that the administration of digestive enzymes of fungal origin like Nortase leads to a 
significantly higher rate of false-positive GM test results compared to that in patients without digestive enzyme treatment.
Keywords Invasive aspergillosis · Critical illness · Galactomannan antigen assay · False positive results · Nortase · 
Digestive enzymes of fungal origin
Abbreviations
BAL  Bronchoalveolar lavage
BDG  (1,3)-Beta-D-glucan
CT  Computed tomography
DEFO  Digestive enzymes of fungal origin
ELISA  Enzyme-linked immunosorbent assay
GM  Galactomannan
IA  Invasive aspergillosis
ICU  Intensive care unit
PPV  Positive predictive value
Introduction
Invasive aspergillosis (IA) is a significant cause of morbidity 
and mortality in immunocompromised patients [1]. Diag-
nosis of IA remains challenging. In 2019, the consensus 
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committee of the European Organization for Treatment of 
Cancer/Mycoses and the Mycoses Study Group (EORTC/
MSG) proposed their revised definition for the diagnosis of 
invasive fungal infections. IA is diagnosed based on findings 
in imaging studies, host factors, histopathology, and micro-
biology [2]. Since the sensitivity of Aspergillus culture or 
microscopy in blood and bronchoalveolar lavage (BAL) is 
often poor, Aspergillus antigen testing is additionally recom-
mended for patients who are at risk or suspicion of IA [3–5].
Galactomannan (GM) is a polysaccharide and a major 
constituent of cell walls of Aspergillus species. It can be 
detected in the host’s bloodstream during invasive infec-
tion [6]. The GM test is a double-sandwich enzyme-linked 
immunosorbent assay (ELISA), which is widely used for 
testing serum and BAL fluid for IA. Sensitivity of GM test-
ing for IA ranges from 70 to 85%, and specificity from 78 to 
91%, in immunocompromised patients [7]. Insufficient data 
are available regarding the test’s performance in patients 
following solid organ transplantation. Sensitivity and speci-
ficity might be decreased in this setting, presumably due to 
less angioinvasive growth in patients with better immune 
defense compared to neutropenic patients [8, 9].
Digestive enzyme preparations are used for enzyme sub-
stitution therapy in exocrine pancreatic insufficiency [10]. 
The advantage of Nortase, a digestive enzyme of fungal 
origin (DEFO) in the ICU setting, in contrast to alternative 
formulas is that the capsule can be opened, and the con-
tained powder is stable to gastric acidity. Therefore, enteral 
application through a feeding tube is feasible. Hence, it is 
the preferred substance used in enteral nutrition of patients 
with exocrine pancreas insufficiency, who are unable to take 
medication orally—in our setting, critically ill patients fol-
lowing major surgery. The powder contains fungal enzymes 
synthesized by Aspergillus oryzae that contains also GM in 
their cell wall like Aspergillus fumigatus. Enzymes derived 
from microbial sources can be obtained over the counter 
and have a long history of safe use within the food industry.
A high number of GM antigenemia episodes was noticed 
in patients receiving Nortase on the Intensive Care Units 
(ICU) of a University hospital. False positive results have 
not been associated with the administration of digestive 
enzymes before. The aim of this study was to investigate 
whether patients receiving Nortase have a higher rate of 
false-positive test results in GM testing.
Methods
Study setting
This is a monocentric, retrospective observational study 
investigating the influence of the application of Nortase on 
the performance of the GM ELISA. A local institutional 
review board approved the study (registration number 
20-269).
Laboratory testing
GM measurement was performed using the Platelia Asper-
gillus antigen ELISA (Bio-Rad Laboratories, Hercules, 
CA, USA). Optical density (OD) indices were rounded to 
one decimal place, with a lower limit of 0.1. A GM OD 
index ≥ 0.5 in two sequential samples including the retesting 
of the first positive sample was considered positive. β-1,3-
D-glucan (BDG) analysis was conducted using the Wako 
BDG assay (FUJIFILM Wako Chemicals Europe, Neuss, 
Germany).
We typically use Nortase (Repha, Langenhagen) as a 
digestive enzyme preparation in the clinical setting. Detailed 
product information, especially regarding the composition 
of the capsule, can be found in the summary of product 
characteristics.
In vitro analysis was performed on five Nortase samples. 
Nortase capsules were opened and suspended in 10 mL of 
normal saline each. The solution was agitated and subse-
quently processed like the serum samples. Three different 
batches were used to exclude contamination by batch.
Study population
All GM-seropositive patients treated at two ICUs of the uni-
versity hospital of Munich between January 2016 and April 
2020 were included in the evaluation. Subsequently, they 
were divided into two groups: group 1, receiving Nortase; 
and group 2, not receiving Nortase. Five to 15 capsules 
Nortase were administered two to four times daily deter-
mined by the attending physician. GM testing was performed 
twice a week, within the clinical routine of our ICUs. In 
addition, all patients receiving Nortase between January 
2016 and April 2020 during their stay at the ICUs were 
evaluated for GM antigenemia.
Data collection
The charts of all patients were reviewed for the diagnosis of 
IA according to the criteria of the EORTC/MSG consensus 
group [2]. However, GM testing is a major factor in these 
criteria. In consideration of the question addressed by this 
study, the more restrictive categories “probable* IA” and 
“possible* IA” had to be applied, which are characterized by 
excluding GM from the criteria for categorization (Table 1). 
To strictly identify those patients who had no evidence of 
IA other than GM antigenemia with respect to the clinical 
characteristics of the study collective (ICU patients rather 
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than hematology‒oncology patients), an additional category 
was applied, i.e., “presumable IA”. All patients who did not 
fulfill the EORTC/MSG criteria for IA but showed evidence 
for IA in two EORTC criteria (clinical features, mycologi-
cal evidence other than GM, host factors) were declared as 
presumable. Accordingly, GM false positivity was defined 
as positive GM test results in patients without any further 
evidence of IA.
Statistical analysis
Statistical analysis was performed with IBM SPSS statistics 
(version 26.0, IBM Corp., Armonk, NY, USA). The dataset 
was evaluated with a focus on significant changes or dif-
ferences in the rate of false-positive test results in both the 
groups. Therefore, the chi-squared test and the Mann‒Whit-
ney U test were used.
Results
GM antigenemia in DEFO patients
Between January 2016 and April 2020, 40 patients at our 
ICUs received Nortase. Thirty (75%) of them developed GM 
antigenemia and were included in the study.
Demographic and clinical data of GM positive 
individuals
In the study period, a total of 65 patients at our ICUs tested 
positive for GM. Thirty patients receiving Nortase were 
allocated to group 1, and 35 others were placed in group 
2. As all patients were critically ill, immunocompromised, 
and often had undergone recent surgery, intense and inva-
sive diagnostic procedures (for example, lung biopsies) were 
performed to rule out IA. For detailed patient characteristics 
and diagnostic workup, see Table 2.
The most frequent reason for the application of Nortase 
was the necessity of enteral feeding through an enteral feed-
ing tube of patients with exocrine pancreatic insufficiency 
due to underlying cystic fibrosis following lung transplanta-
tion (27/30 patients). Three patients had different reasons for 
exocrine pancreatic insufficiency.
Assessment of validity of GM testing
In the Nortase group, patients were diagnosed with proven, 
probable*, possible* and presumable IA according to the 
(modified) EORTC/MSG criteria in 0, 4, 0 and 4 cases 
respectively (Fig. 1) [2]. Twenty-two cases positive for 
GM did not meet any of the clinical, histopathological or 
microbiological criteria, apart from antigenemia, allowing 
the diagnosis of proven, probable*, possible* or presumable 
IA. All of these cases underwent an intensive diagnostic 
workup, including CT scan and histopathology of the suspi-
cious body site. Autopsies were performed on two deceased 
patients and showed no sign of IA. Consequently, these 22 
patients (73.3%) with GM antigenemia as the only parameter 
indicating IA were considered as false-positive.
In contrast, 8, 11, 1 and 9 patients allocated to group 
2 were diagnosed with proven, probable*, possible*, and 
presumable IA, respectively, according to the (modified) 
EORTC/MSG criteria [2]. The remaining six patients 
(17.1%) with GM antigenemia as the only parameter indi-
cating IA were considered false positives (see Fig. 1). For 
details on patient characteristics classified as presumable 
IA, see Table 3.
Including all patients, the positive predictive value of the 
GM antigen test was 0.57. When comparing the two sub-
groups, the test performance in group 2 with a positive pre-
dictive value (PPV) of 0.83 was significantly better than in 
group 1 with a positive predictive value of 0.27 (p < 0.001).
Chi-squared analysis demonstrated that patients allocated 
to group 1 had a false-positive GM test significantly more 
often compared to group 2 (p < 0.001).
Table 1  EORTC/MSG 
and modified definitions 
of probability of invasive 
aspergillosis
Note: Modified categories in italics; IA invasive aspergillosis; +* evidence other than GM seropositivity; 
–* no evidence apart from GM seropositivityote; #for category presumable 2 criteria must be fulfilled
Category Host factor Clinical feature Myco-
logical 
evidence
Probable IA  +  +  + 
Probable* IA  +  +  + *
Possible IA  +  + –
Possible* IA  +  + –*
Presumable IA#  ±  ±  + */–
Proven IA Microscopic or cultural finding of Aspergillus spp. 
from sterile material
No evidence for IA  ≤ 1 criterion of probable IA*
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Table 2  Patient characteristics 
and diagnostic work up in both 
groups
Note: BAL bronchoalveolar lavage, IA invasive aspergillosis, ARDS Acute respiratory distress syndrome, 
CT Computed tomography
*According to the criteria of the EORTC/MSG consensus guidelines [2]
Group1 “Nortase 
therapy”: n (%) or 
median [range]
Group2 “no Nortase 
therapy”: n (%) or 
median [range]
Number of patients 30 (46.2%) 35 (53.8%)
Age: years 37 [21, 67] 58 [22, 79]
Gender: male/female 13/17 (43.3%/56.7%) 19/16 (54.3%/45.7%)
Cystic fibrosis 27 (90%) 2 (5.7%)
Solid organ transplantation 28 (93.3%) 19 (54.3%)
Sepsis 0 (0%) 7 (17.1%)
ARDS 0 (0%) 6 (11.4%)
Microbiological workup (i.e., culture from BAL or sputum, 
urine, blood, sterile body fluid samples)
30 (100%) 35 (100%)
Cultivation of Aspergillus spp. 8 (26.7%) 26 (74.3%)
CT of body site suspicious for IA 29 (96.7%) 35 (100%)
CT positive for IA* 4 (13.3%) 17 (48.6%)
Histopathology of biopsy from body site suspicious for IA 28 (93.3%) 24 (68.6%)
Histopathology positive for invasive mold infection 0 (0%) 10 (28.6%)
Performed clinical examination 30 (100%) 35 (100%)
In-hospital mortality 17 (56.7%) 21 (60%)
Autopsy performed 2 (7%) 3 (8.6%)
Autopsy positive for IA 0 (0%) 2 (5.7%)
Antifungal therapy of IA 24 (80%) 31 (88.6%)
Fig. 1  Distribution of false-
positive GM test results in both 
groups
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Comparison of GM levels and kinetic patterns
In all the false-positive patients in group 1, GM antigen-
emia occurred during the administration of Nortase. Four-
teen patients (63.6%) already showed positive GM results in 
the first or second measurement after initiation of Nortase 
therapy. Five patients (22.7%) already showed negative GM 
results in the first or second measurement after cessation of 
Nortase therapy.
The median GM index in all true positive patients was 
1.3, and in all false-positive patients it was 1.7. Statistical 
evaluation with the Mann‒Whitney U test showed no sig-
nificant difference (p = 0.88) between these groups. There 
was also no significant difference in GM levels between 
true positive and false positive between each group (group 
1 (p = 0.45), group 2 (p = 0.40)).
Antifungal therapy
Systemic antifungal therapy was administered to 24 patients 
(80%) in group 1, and to 31 patients (88.6%) in group 2. 
They received voriconazole, liposomal amphotericin B, 
caspofungin, or isavuconazole depending on patient fac-
tors. According to our data, 16 (53.3%) patients allocated to 
group 1 and two patients (5.7%) allocated to group 2 retro-
spectively received antifungal therapy due to false-positive 
GM results. In contrast, none of the patients with evidence 
for IA was deprived of antifungal therapy in the two groups.
Determination of GM and BDG levels in in vitro 
Nortase samples
In vitro analysis of Nortase samples of three different 
batches suspended in 10 mL normal saline each yielded a 
median GM index of 2.32 (range: 2.25‒7.01). The speci-
mens were subjected to further analysis for fungal anti-
gens by testing for the panfungal marker BDG. All Nortase 
batches were found to contain high concentrations of BDG 
(median 1034.8 pg/mL (range: 975‒1034.8)).
Discussion
GM screening is a valuable tool for the early detection of 
IA [3, 4]. In immunocompromised patients, the test perfor-
mance is known to be relatively good [7–9]. Our finding of a 
PPV of 0.83 for patients without Nortase therapy is in good 
agreement with the previously published data. However, we 
observed that 75% of our ICU patients receiving Nortase 
developed GM antigenemia. Deterioration of the test’s per-
formance by the administration of digestive enzymes has not 
been described before. This retrospective analysis aimed to 
determine whether the antigen-based diagnosis was indeed 
correct.
The probability of IA diagnosis was graded by applying 
the scientific criteria for invasive mold infections defined 
by the EORTC/MSG consensus group [2].GM seropositiv-
ity is a major factor (criterion “mycological evidence”) for 
grading, but with respect to the question addressed by this 
study, we had to exclude antigen testing from the definitions, 
making them even more restrictive (modified categories: 
Table 3  Characteristics of 












1 x - x
2 x - x
3 x - x
4 x - x
5 x - x
6 x - x
7 x - x
8 x - x
9 x - x
10 x - x
11 x - x
12 - x x
13 - x x
Note: no number of patient, IA invasive aspergillosis, grey Nortase group, yellow no 
Nortase group
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probable* and possible* IA; see Table 1). Notably, the 
EORTC/MSG criteria were developed for severely immu-
nocompromised patients with cancer and for hematopoietic 
stem cell transplant recipients. These patients differ from 
typical ICU patients regarding disease presentation as well 
as test performances. The consensus group addressed this 
issue but was unable to generate recommendations for this 
special population [2, 11]. Alternative algorithms have been 
proposed for ICU patients but are not yet used in clinical 
routine [12]. In our study, several patients met two of the 
three criteria for probable IA, but not the third criterion, i.e., 
a clinical feature. These patients were declared as presum-
able IA as their specific probability for IA was high. The rea-
son for a lack of clinical features in these patients is obvious 
as differences in disease presentation between neutropenic 
cancer patients and ICU patients are well known by now. For 
instance, radiological findings in ventilated patients are non-
specific so broadening the radiological criteria seems valu-
able [12, 13]. Therefore adding the category “presumable 
IA” allowed us to make the grading of ICU patients very 
close to the canonical EORTC/MSG guidelines (Table 1).
It is important to point out, though, that most of the IA 
patients (64.9%) in our study were classified along the com-
mon EORTC/MSG categories proven, probable, and pos-
sible IA (still excluding GM antigenemia).
Our data suggest that a dramatically high proportion of 
73.3% of all patients receiving Nortase showed false-positive 
results in Aspergillus antigen testing (control group: 17.1%).
However, how can we tell that they were false positive?
All GM positive patients received an intense diagnos-
tic workup, which included microbiological testing such as 
cultures from different body sites, CT imaging, and histopa-
thology of the lung. Autopsy was performed in two patients, 
with neither histology nor culture yielding any evidence for 
IA. Upon exclusion of GM positivity from the IA defining 
criteria, these 22 and 6 patients (Nortase vs. control group) 
did not even meet the criteria for possible*/presumable IA; 
they had no evidence for infection.
GM antigenemia kinetics underlined suspected false posi-
tivity as GM levels abruptly increased within a few days 
after the administration of Nortase and were resolved in 
many cases after its discontinuation.
In vitro testing of Nortase samples of different batches 
yielded highly positive results in the GM and BDG assays. 
In a critical care setting, DEFO are usually administered 
through an enteral feeding tube. Presumably, impaired 
mucosal integrity allows for GM translocation into the 
bloodstream resulting in seropositivity [14]. Intestinal 
hyperpermeability with translocation from the gut can often 
be seen in critical illness [15], possibly even more relevant 
in critical ill patients with cystic fibrosis [16]. This might 
explain why the influence of DEFO on the performance of 
the GM test has not been described before—it might not be 
a problem beyond ICU settings.
In our study, more than 80% of all patients who devel-
oped GM antigenemia received systemic antifungal therapy 
prior to the results of a further diagnostic workup. This is 
concordant with a preemptive strategy, meaning antifungal 
therapy based on biomarker surveillance [17]. According 
to our data, 16 patients allocated to group 1 (53.3%), but 
only 2 patients allocated to group 2 (5.7%), may have retro-
spectively received antifungal therapy due to possibly false-
positive GM results.
Our routine has been changed by these findings. The 
application of Nortase in patients who are at risk of IA must 
be strictly limited. Patients who develop GM antigenemia 
following DEFO application do not get antifungal therapy 
as long as there is no other sign of IA, as false positivity 
is probable. If there is any doubt, DEFO therapy should 
be discontinued and enteral nutrition must be initiated by 
peptide diets whose resorption is independent of pancreatic 
enzymes.
False positive GM antigenemia has been described before 
and was associated with the administration of generic piper-
acillin/tazobactam [18–22], hypercaloric drinks [23], anti-
fungal prophylaxis [24, 25], and even ice-pop ingestion and 
pasta. In most cases, the proposed mechanism for false posi-
tivity was the contamination of the product with GM. Based 
on the literature and our in vitro results of GM and BDG 
testing, we assume that the applied purification techniques 
for digestive enzymes from fungal cultures cannot prevent 
contamination of the drug with cell wall polysaccharides. 
As in vitro testing of Nortase for BDG also turned out to 
be positive, this alternative antigen test cannot be expected 
to help confirm the diagnosis. Since BDG is a panfungal 
biomarker, which is also used for the diagnosis of Candida 
and Pneumocystis infections, we speculate that the admin-
istration of DEFO could also result in misdiagnosis of other 
fungal infections.
This study has certain limitations. First, the in vivo analy-
sis has a retrospective study setting, based on a relatively 
low number of patients. Nevertheless, compared to previous 
studies that investigated potential sources of false-positive 
GM, this number is rather high [24, 25]. Second, the two 
groups differ greatly regarding age. This is linked to different 
underlying diseases, as DEFO are typically given to patients 
with end-stage cystic fibrosis following lung transplantation, 
who are most of the time of young age when receiving the 
new lung. An age- and diagnosis- dependent influence on 
the rate of false-positive GM tests appears not to be likely, 
though. Third, the case definitions of IA have been modified, 
resulting, in a deviation from the scientific gold standard. 
Therefore, a careful interpretation of the results is required, 
and comparability with other studies is limited.
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Conclusions
In conclusion, the GM assay allows the detection of Asper-
gillus antigen with high sensitivity and specificity in the 
serum of patients with IA who did not have Nortase therapy. 
Factors resulting in false-positive GM testing must be known 
to avoid misdiagnosis, unnecessary treatment, and extrane-
ous costs. GM antigenemia in patients receiving degestive 
enzymes of fungal origin like Nortase should be interpreted 
with caution due to the significantly higher rate of false-
positive test results in contrast to patients without Nortase 
therapy. In our opinion, the Summary of Product character-
istics need to be adjusted to draw the attention of clinicians 
to these new findings.
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